Yan Wang
Los Angeles
Education
Sc.D., biostatistics and environmental health, and M.S., environmental health, Harvard T.H. Chan School of Public Health; B.S., environmental science, and B.Econ, economics, Peking University, China
Summary of Experience
Dr. Wang specializes in the application of advanced biostatistics techniques in the field of health economics and outcomes research (HEOR). He has developed statistical methodologies in the fields of causal inference, survival analysis, penalized regression, smoothing techniques, and fast computation methods for extremely large datasets. He also has deep experience applying state-of-the-art statistical methods to biomedical research using large databases, such as Medicare data. Dr. Wang has contributed to studies in a wide range of disease areas, including oncology, metabolic disorders, neurology, immunology, cardiovascular disease, dermatology, and rheumatology. His case work includes network meta-analysis, matching-adjusted indirect comparisons, real-world database analysis, clinical trial data analysis, cost-per-outcome analysis, and cost-effectiveness analysis. His research has been published in multiple peer-reviewed journals, including The New England Journal of Medicine, The BMJ, Epidemiology, Biostatistics, and Environmental Health Perspectives, and his research has been presented at international conferences.
Selected Publishing
-
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
Cancer Immunology, Immunotherapy, 2022
2022Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Yan Chen Y, Wang Y, Betts KA, Shoushtari AN
-
Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial
Journal of Medical Economics, 2022
2022Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP
-
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
Dermatology and Therapy, 2022
2022Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, Puig L
-
Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit
Clinical Therapeutics, 2022
2022Desai N, Xie J, Wang Y, Sutton MB, Whang J, Fine JT, Garrison LP
-
Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
Dermatology and Therapy, 2021
2021Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, Augustin M
-
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
Journal of the American Academy of Dermatology, 2021
2021Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW